Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
Background Epithelial sodium channel (ENaC) is an important regulator of airway surface liquid volume; ENaC is hyperactivated in cystic fibrosis (CF). ENaC inhibition is a potential therapeutic target for CF. Here, we report in vitro and in vivo results for BI 1265162, an inhaled ENaC inhibitor curr...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-12-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/6/4/00429-2020.full |